ADMA Biologics (ADMA)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of ADMA Biologics (ADMA)
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
Key Insights
Critical company metrics and information
Share Price
$19.31Market Cap
$4.56 BillionTotal Outstanding Shares
236.39 Million SharesTotal Employees
624Dividend
No dividendIPO Date
October 17, 2013SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.admabiologics.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow, Continuing | $12.55 Million |
Net Cash Flow | $12.55 Million |
Net Cash Flow From Operating Activities | $86.05 Million |
Net Cash Flow From Investing Activities | $-7.23 Million |
Net Cash Flow From Operating Activities, Continuing | $86.05 Million |
Net Cash Flow From Investing Activities, Continuing | $-7.23 Million |
Net Cash Flow From Financing Activities | $-66.27 Million |
Net Cash Flow From Financing Activities, Continuing | $-66.27 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Selling, General, and Administrative Expenses | $66.34 Million |
Income Tax Expense/Benefit | $5.22 Million |
Cost Of Revenue | $195.50 Million |
Gross Profit | $187.31 Million |
Income/Loss From Continuing Operations After Tax | $68.13 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Operating Income/Loss | $114.89 Million |
Research and Development | $1.87 Million |
Revenues | $382.81 Million |
Operating Expenses | $72.41 Million |
Benefits Costs and Expenses | $23.00 Million |
Nonoperating Income/Loss | $-41.54 Million |
Income/Loss From Continuing Operations Before Tax | $359.81 Million |
Depreciation and Amortization | $8.21 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Net Income/Loss Attributable To Parent | $68.13 Million |
Diluted Average Shares | $485.12 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Basic Average Shares | $465.89 Million |
Basic Earnings Per Share | $0.29 |
Diluted Earnings Per Share | $0.28 |
Net Income/Loss | $68.13 Million |
Net Income/Loss Available To Common Stockholders, Basic | $68.13 Million |
Costs And Expenses | $259.58 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Liabilities | $158.73 Million |
Liabilities And Equity | $390.62 Million |
Accounts Payable | $16.02 Million |
Current Assets | $318.19 Million |
Fixed Assets | $53.69 Million |
Noncurrent Assets | $72.42 Million |
Other Current Liabilities | $28.87 Million |
Inventory | $171.80 Million |
Other Non-current Assets | $18.25 Million |
Other Current Assets | $146.39 Million |
Assets | $390.62 Million |
Noncurrent Liabilities | $113.84 Million |
Intangible Assets | $485,000.00 |
Equity | $231.89 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Current Liabilities | $44.89 Million |
Equity Attributable To Parent | $231.89 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Related Companies
View additional S&P 500 companies similar to ADMA Biologics (ADMA)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.